Sarepta CEO Vows To Get Exondys 51 Into EU Despite CHMP Negative Trend Vote

 
• By Sten Stovall

CEO Doug Ingram aims to change EMA panel's view with a re-review, but concedes that EU arrival of the controversial DMD drug will now take longer than first thought.

DMD
Sarepta’s DMD Drug Eteplirsen Has Been Rebuffed By European Regulatory Advisors • Source: Shutterstock

More from New Products

More from Scrip